Product Images Terazosin

Description: This is a medication called Terazosin, available in capsule form with a strength of 2mg. The package contains 30 capsules and is for prescription use only. The dosage information can be found in the package insert. It should be stored at a temperature between 20°C - 25°C (68°F - 77°F) in order to comply with USP controlled room temperature guidelines. It is important to keep this medication out of the reach of children and store it in its original container. It should be protected from light and moisture. The medication has been repackaged by Northwind Pharmaceuticals and the original manufacturer is Avet Pharmaceuticals Inc. with the lot number 0000000000. The active ingredient is terazosin hydrochloride, which is equivalent to 2mg per capsule. The original product was repackaged from NDC 23155-736-XX and has a GTIN code of 00351655915523. The serial number is 000000000000000 and the expiration date is 00/00/0000.*

This text provides information on Figure 2, which shows the mean change in total symptom score from baseline in a long-term, open-label, non-placebo controlled study involving 494 participants. The study spanned over a period of 30 months. The text also mentions that there is a statistically significant difference (p < 0.05) compared to the baseline mean of 10.7.*

This is a figure showing the mean change in peak flow rate from baseline in a long-term, open-label, non-placebo controlled study. The study included 494 participants. The graph displays the mean change in peak flow rate over time, with the x-axis representing the months (from 0 to 30) and the y-axis representing the change in peak flow rate (in mL/sec). The graph shows a decrease in peak flow rate from baseline throughout the study period. The footnote indicates that the mean change from baseline is statistically significant (p<0.05) compared to the baseline mean of 9.9.*

The text provides information on the mean changes in blood pressure from baseline to the final visit in all double-blind placebo-controlled studies. The data is divided into two groups: normotensive patients (with DBP < 90 mmHg) and hypertensive patients (with DBP > 90 mmHg). The text presents the mean changes in SBP and DBP values for each group. The data compares the effects of a placebo treatment versus terazosin treatment. The text also indicates that the values with an asterisk (*) are statistically significant (p<0.05) when compared to the placebo.*

Not available.*

This is a table showing the discontinuation rates of patients with benign prostatic hyperplasia during placebo-controlled trials of the medication terazosin. The table provides percentages of patients who experienced various side effects and discontinued the treatment. Some of the reported side effects include fever, headache, postural hypotension, syncope, nausea, dizziness, vertigo, dyspnea, blurred vision/amblyopia, and urinary tract infection.*

TABLE 4: Discontinuation during placebo-controlled trials for hypertension. The table shows the percentage of patients experiencing adverse effects and discontinuing treatment with terazosin and placebo. Adverse effects include asthenia, headache, palpitations, postural hypotension, syncope, tachycardia, nausea, peripheral edema, dizziness, paresthesia, somnolence, dyspnea, nasal congestion, and blurred vision.*